Dr. Michael Lusiola has been appointed as the Chief Executive Officer (CEO)/Director-General of Kenya BioVax Institute (KBI) with effect from June 2022.
Dr. Lusiola takes over from Dr. Rabera Kenyanya who has been the Acting CEO/DG from December 2021.
He has previously worked as a VP in global clinical development (immunotherapies) at AstraZeneca Pharmaceuticals, UK and USA.
He attained his graduate and post-graduate academic qualifications from Harvard USA (post-graduate, global public health), Reading UK (post-graduate, business management and administration), Liverpool and Aston UK (post-graduate, evidence-based medicine) and Nairobi Kenya (graduate, pharmacy).
Dr. Michael Lusiola has memberships at the Institute of Clinical Research (MICR) UK, the Royal Society of Medicine (MRSM) UK, the Royal Pharmaceutical Society (MRPS) UK, and the International Society for Vaccines.